ACM
EGRX

Aquatic Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Aquatic Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,900
Closed -$54K – 1812
2023
Q1 		$54K Sell
1,900
-10,700
-85% -$318K ﹤0.01% 880
2022
Q4 		$368K Buy
12,600
+6,500
+107% +$207K 0.03% 578
2022
Q3 		$161K Buy
+6,100
New +$224K 0.02% 656

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Aquatic Capital Management's EGRX Position: Q2 2023 in Review

Aquatic Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 1,900 shares — an estimated $54K sold.

Aquatic Capital Management first reported a position in EGRX in Q3 2022 and held it in 3 quarters. The position peaked at $368K in Q4 2022. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • Aquatic Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Aquatic Capital Management sold 1,900 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $54K.
  • Aquatic Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2022 and held it in 3 quarters.
  • Aquatic Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $368K in Q4 2022.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Aquatic Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.